Unlike traditional approaches, Bayesian methods enable formal combination of expert opinion and objective information into interim and nal analyses of clinical trials data. However, most previous Bayesian approaches have based the stopping decision on the posterior probability content of one or more regions of the parameter space, thus implicitly determining a loss and decision structure. In this paper, we o er a fully Bayesian approach to this problem, specifying not only the likelihood and prior distributions, but appropriate loss functions as well. At each data monitoring point, we enumerate the available decisions and investigate the use of backward induction, implemented via Monte Carlo methods, to choose the optimal course of action. We then present a forward sampling algorithm that substantially eases the analytic and computational burdens associated with backward induction, o ering the possibility of fully Bayesian optimal sequential monitoring for previously untenable numbers of interim looks. We show that forward sampling can always identify the optimal sequential strategy in the case of a one-parameter exponential family with a conjugate prior and monotone loss functions, as well as the best member of a certain class of strategies when backward induction is infeasible. Finally, we illustrate and compare the forward and backward approaches using data from a recent AIDS clinical trial.
Introduction
The design, interim monitoring, and nal analysis of clinical trial data is one of the most important and widely used elds of biostatistical endeavor. In the last ten to fteen years, Bayesian methods have gained increasing popularity as an alternative to traditional frequentist monitoring methods. They allow for greatly simpli ed designs, due to the independence of the inference from the stopping rule. They also enable more realistic sample size determination and are better able to respond to ethical dilemmas regarding patient treatment assignment, due to their incorporation of the full range of the (possibly patient-speci c) expert prior belief (Kadane and Sedransk, 1980; Kadane, 1986 Kadane, , 1996 . Thorough reviews of the use of Bayesian methodology in clinical trials (and its advantages over traditional methods) are provided by Berry (1991 Berry ( , 1993 and Spiegelhalter, Freedman and Parmar (1994) Despite these advantages, practicing biostatisticians and clinicians have been reluctant to use Bayesian methods. The primary reason for this rejection is their perceived \subjectivity," due to their dependence on a prior distribution for the relevant model parameters. The most common remedy suggested for this weakness is simply to repeat the procedure with a di erent prior distribution, and see if any signi cant change in the posterior results. An alternate approach is prior partitioning (Carlin and Louis, 1996; Carlin and Sargent, 1996) , which instead attempts to characterize the class of priors leading to a particular decision (e.g., stop the trial and decide in favor of the treatment) for a given dataset.
These approaches have been criticized by some authors (e.g. Lindley, 1994, and Berry, 1995) for failing to go beyond simply summarizing posterior probabilities of various subsets of the parameter space. These authors note that the Bayesian methodology is ideally suited for blending with formal decision-theoretic tools in settings where policymakers must do more than simply summarize a trial's results (e.g., in determining whether it is ethical to continue a given trial). More speci cally, Stangl (1995a) and Kadane (1997) observe that since a particular utility is implicit in any inference made, it would be far more sensible to incorporate utility explicitly into the analysis. Spiegelhalter et al. (1994) and others defend the probability-only approach by pointing out the extreme di culty in choosing meaningful and appropriate utility functions, since, unlike probabilities, their scales are often rather arbitrary, adding to practitioners' discomfort when discussing them. Still, progress continues to be made in this area; see for example Berry and Ho (1988) for a utility function on a dollar scale, and Stangl (1995b) for a simple utility relating patient survival and quality of life.
Yet perhaps the most compelling reason for avoiding the fully Bayesian decision-theoretic approach has been the great analytical and computational complexity in implementing its solution via backward induction (see e.g. DeGroot, 1970, Chapter 12) . Some preliminary work has been done in this area, but it has been restricted to simple model settings, such as one-sided tests of a univariate parameter (Berry and Ho, 1988) and binary outcome settings (Lewis and Berry, 1994) with few (typically 2 or 3) backward steps (interim looks at the data).
In Section 2 of this paper, we describe a class of two-sided clinical trial sequential decision problems (i.e., their likelihood, prior, and loss structures), and brie y outline their solution via the traditional backward induction approach. Then in Section 3, we present a forward sampling algorithm which can produce the optimal stopping boundaries for a broad subclass of these problems at far less computational and analytical expense. In addition, this forward sampling method can always be used to nd the best boundaries within a certain class of decision rules, even when backward induction is infeasible. Section 4 illustrates and compares these two approaches in the context of a recent AIDS clinical trial, con rming the accuracy and broad applicability of forward sampling. Section 5 brie y summarizes our ndings, and suggests aspects of the fully Bayesian approach to clinical trials requiring further work. Finally, Appendices A and B provide theoretical and implementational support for the backward and forward approaches, respectively.
2 Bayesian sequential decision analysis 2.1 Model and loss structure Suppose that a clinical trial has been established to estimate the e ect of a certain treatment. Information already available concerning is summarized by a prior distribution p( ). As patient accrual and followup is getting underway, the trial's data safety and monitoring board (hereafter referred to simply as \the board") agrees to meet on K prespeci ed dates to discuss the trial's progress and determine whether or not it should be continued. At each monitoring point k 2 f1; : : :; Kg, some cost A k will have been invested in obtaining a new datapoint x k having distribution f(x k j ), enabling computation of the updated posterior distribution p( jx 1 ; : : :; x k ). It is convenient to think of k = 0 as an additional, preliminary monitoring point, allowing the board to determine whether the trial should be run at all, given only the prior and the set of costs fA k g.
Suppose that for the treatment e ect parameter 2 <, large negative values suggest superiority of the treatment, while large positive values suggest superiority of the placebo (inferiority of the treatment). Suppose further that in conjunction with substantive information and clinical expert opinion, an indi erence zone (c 2 ; c 1 ) can be determined such that the treatment is preferred for < c 2 , the placebo for > c 1 , and either decision is acceptable for c 2 < < c 1 . In such a setting, one might typically set c 1 = 0 but take c 2 < 0, thus requiring a \clinically signi cant" bene t from the treatment to o set its increased cost or unpleasant side e ects. Given the posterior distribution of the treatment parameter at this nal time point, p( jx K ), the best decision is that corresponding to the smaller of the two posterior expected losses, L 
Backward induction
To obtain the optimal Bayesian decision in the sequential setting at any time point other than the last, one must consider the probability of data values that have not yet been observed. This requires \working the problem backward" (from time K back to time 0), a process referred to as backward induction (see e.g. DeGroot, 1970, Chapter 12 
where R is a bit awkward, it is not particularly di cult or high-dimensional. Rather, the primary hurdle arising from the backward induction process is the explosion in bookkeeping complexity arising from the resulting alternating sequence of integrations and minimizations. This is illustrated for time K ? 2 in Appendix A, which also
shows that the number of Monte Carlo generations required to implement the backward induction solution increases exponentially in the number of backward steps.
3 Optimal decision analysis by forward sampling
The backward induction method's geometric explosion in both organizational and computational complexity as K increases motivates a search for an alternative approach. We now describe a forward sampling method which permits nding the optimal sequential decision in a prespeci ed class of such decisions. We implement this method when the class consists of decision rules of the following form: At each step k, for E( jx 1 ; : : :; x k ) k;L , make decision d 1 (stop and choose the treatment);
for E( jx 1 ; : : :; x k ) > k;U , make decision d 2 (stop and choose the placebo); for k;L < E( jx 1 ; : : :; x k ) k;U , make decision d 3 (continue sampling).
Appendix B provides su cient conditions to ensure that the optimal strategy is of this form.
Customary normal mean, binomial, and Poisson models meet these conditions.
Note that k;L k;U , with equality always holding for k = K (i.e., K;L = K;U K ). This special structure motivates the following forward sampling algorithm, which for comparison with Section 2 is illustrated in the case K = 2. Suppose an independent sample ( j ; x K?1;j ; x K;j ); j = 1; : : :; G is drawn via composition from the joint density p( ;
When K = 2, decision rules can be indexed by the (2K ? 1 = 5)-dimensional vector = ( K?2;L ; K?2;U ; K?1;L ; K?1;U ; K ) 0 . Suppose that at the i th iteration of the algorithm, a current estimate (i) of the optimal rule of this form is available. For each of the simulated parameter-data values, the loss incurred under the current rule (i) can be computed as follows:
Monte Carlo estimate of the posterior expected loss under decision rule (i) . If the current estimate is not the minimum value, it is adjusted to (i+1) , and the above process is repeated. At convergence, the algorithm provides the desired optimal stopping boundaries.
Several remarks about this algorithm are in order. First, note that many of the x K;j values (and some of the x K?1;j values as well) will not actually gure in the determination of L, since they contribute only to the later conditions in the decision tree (4). These cases correspond to simulated trials that stopped before these later data values were actually observed; ignoring them in a given replication creates the proper marginal distribution of the parameter and the observed data (if any). Indeed, note that when E( ) = 2 ( K?2;L ; K?2;U ], all of the sampled values fall into one of the rst two cases in (4). Second, L is not likely to be smooth enough as a function of (i) to allow its minimization via standard methods, such as a quasi-Newton method. In our work, we have obtained better results by applying a more robust, univariate method (such as a golden section search) sequentially in each coordinate direction, i.e., within an iterated conditional modes algorithm (see Besag, 1986 ).
The main advantage of this approach over backward induction is clear: since the length of is 2K?1, the computational burden in forward sampling grows linearly in K, instead of exponentially.
The associated bookkeeping and programming is also far simpler. Finally, the forward sampling algorithm is easily adapted to more advanced loss structures. For example, switching back to the positive part loss functions (1), a change that would cause substantial complications in the backward induction solution, leads only to the corresponding change in the forward sampling scoring rule (4).
A potential disadvantage of the forward sampling algorithm is that it replaces a series of simple minimizations over discrete nite spaces (a choice among 3 alternatives) with a single, more di cult minimization over a continuous space (< 2K?1 ). One might well wonder whether this minimization is any more feasible for large K than backward induction. Fortunately, even when the exact minimum is di cult to nd, it should be possible to nd a rule that is nearly optimal via grid search over -space, meaning that approximate solutions will be available via forward sampling even when backward induction is infeasible.
It is critical to get a good estimate of each of the components of the optimizing , and not just the \components of interest" (typically, the early components of , near the current time point),
for otherwise there is a risk of nding a local, rather than a global, minimum. As such, one may want to sample not from the joint distribution p( ; x 1 ; : : :; x K ), but from some modi cation of it designed to allow more realizations of the latter stages of the decision tree (4). To correct for this, one must then make the appropriate importance sampling adjustment to the L j scores in (4).
By deliberately straying from the true joint distribution one is sacri cing overall precision in the estimated expected loss in order to improve the estimate of the later elements of . As such, the phrase \unimportance sampling" might be used to refer to this process.
Application and comparison of methods
The methods of Sections 2 and 3 are now illustrated and compared using an AIDS clinical trial dataset originally reported and analyzed by Jacobson et al. (1994) . The data are from a double-blind randomized trial that compared the drug pyrimethamine with placebo for preventing toxoplasmic encephalitis (TE), a major cause of morbidity and mortality among AIDS patients. In a Bayesian reanalysis of these data, Carlin et al. (1993) implying that for this cost, loss, and distributional structure, it is optimal to continue sampling. versus for the three decisions (i = 1; 2; 3) computed via backward induction, using the normal/normal model with variances estimated from TE trial data. Choosing the treatment is optimal for < ?:65, while choosing the placebo is optimal for > :36; otherwise, it is optimal to continue the trial to time K ? 1. However, a one-step-back analysis at time K ? 1 using p( jx K?1 ) as the prior nds that L (K?1) 2 is now the smallest of the three values by far, meaning that the trial should now be stopped and the treatment discarded. This con rms the board's actual recommendation, albeit for a slightly di erent reason (excess deaths in the drug group, rather than a lack of excess TE cases in the placebo group). forward Monte Carlo draws we were able to con rm the values found above ({.64 and .36) via backward induction. While the continued need for grid search is a nuisance, we remark that for forward sampling, the same G Monte Carlo draws may be used for each candidate value.
As an illustration of the broader applicability of forward sampling, we extend the problem in three signi cant ways. First, we extend to the case K = 3, so that the 1/15/91 likelihood now plays the role of the prior, with the remaining three monitoring points representing accumulating data.
Second, we return to the \positive part" loss structure (1), simply by adding this modi cation to our de nition of the Monte Carlo losses L j , as in (4). Note that this is still a monotone loss speci cation (hence suitable for forward sampling in the restricted class that depends only on the posterior mean), but one which leads to substantial complications in the backward induction solution. Finally, the positive part loss allows us to apply the ideas in the nal paragraph of Appendix B, ordering the losses so that incorrect decisions are penalized more heavily the later they are made. Speci cally, we take s
= k + 3, for k = 0; 1; 2; 3.
Since forward sampling cannot be implemented with the improper prior suggested by the 1/15/91 likelihood in Figure 1 , we instead retain a normal speci cation, i.e. a N( ; 2 0 ) with = 0 and 2 0 = 5. This prior is quite vague relative to our rather precise likelihood terms. We also retain our uniform cost structure, A k = :1 for all k, and simply set Finally, we investigate the robustness of our conclusions by replacing our normal likelihood with a much heavier-tailed Student's t with = 3 degrees of freedom. Since there is now no longer a single su cient statistic for , the optimal rule need not be solely a function of the posterior mean, but we may still use forward sampling to nd the best member in this class of posterior mean-based rules. We retain our previous prior, cost, and loss structure, and set compare to the elements of the vector, but is otherwise unchanged. We now obtain 1;L = ?0:503 and 1;U = 0:205, a slightly narrower interval than before (probably since the t 3 has a more concentrated central 95% region than the normal for a xed variance), but one which still easily contains the observed 7/31/91 mean of .021.
Discussion
In this paper we have described the traditional backward induction approach to the two-sided univariate sequential decision problem, with special application to the problem of monitoring clinical trials. We have also described and illustrated a forward sampling approach that dramatically reduces the computational and analytical overhead, and o ers the possibility of fully Bayesian sequential decisionmaking with numerous interim looks, a previously untenable problem.
In the case of a one-parameter exponential family likelihood, our development in Appendix B
shows that forward sampling may be used to nd the optimal rule based solely on the posterior mean. In a very general parametric case, the optimal sequential strategy could be a complex ). In such a case, for the particular loss function in question it may be possible to reduce the class of possible optimal strategies. But as our t 3 example in Section 4 suggests, for practical purposes it may not be necessary to nd the optimal sequential strategy. Forward sampling can be used to evaluate general sequential strategies of any speci ed form. If the class of sequential strategies o ered to the algorithm is reasonably broad, the best strategy in that class is likely to be quite good, even if it is not optimal in the class of all sequential strategies. This constitutes a distinct advantage of the forward sampling algorithm. When backward induction becomes infeasible, as it quickly does even in simple cases, it o ers no advice about what sequential strategy to employ. Forward sampling, however, can be applied in such a situation with a restricted class of sequential strategies to nd a good practical one even if it is not the best possible.
Armed with this more powerful computational framework, many challenges in the practical application of fully Bayesian methods to clincial trial monitoring may now be tackled. Better guidelines for the proper choice of loss functions l (k) i (d i ; ) and corresponding sampling costs fA k g, expressed in either dollars earned or lives saved, are needed. For example, if an incorrect decision favoring the treatment were judged C times more egregious than an equivalent one favoring the placebo (i.e., one where the true value lay equally far from the indi erence zone but in the opposite direction), we might choose s
2 . Extensions to more realistic trial settings (beyond the simple normal likelihood and prior illustrated in Section 4) would also be welcome. Finally, the forward sampling technology shows promise for application to more general sequential settings (e.g., multivariate patient response), and even some xed sample designs (e.g., allocating an optimal number of treatments and blocks to a xed total sampling budget) where traditional Bayesian approaches are intractable. In this vein, the paper by Hardwick and Stout (1995) (5) and (6), it is clear that the complexity of the calculation required for L 3 grows exponentially in the number of backward steps.
Working in a categorical data setting, Vlachos and Gelfand (1996) the optimal sequential decision rule takes the form presented at the beginning of Section 3. In particular then, for the usual normal, binomial and Poisson sampling models, the forward sampling approach will be applicable.
Suppose then for data point x k the likelihood is f(x k j ) = h(x k ) exp w k ( x k ? b( ))], where E(x k j ) = b 0 ( ), with inverse transformation = ( ), and V ar(x k j ) w ?1 k V ( ), where V ( ) = b 00 ( ( )) and the w k are known constants, perhaps re ecting summarization of more raw data. The conjugate prior for (Morris, 1983, p.525 
It is optimal to sample if L (0) 
2 , note from DeGroot (1970, p.280 ) that the risk of the optimal two-look procedure is no larger than that of the optimal one-look procedure. Thus L (0) 3;2 ( ), the continuation risk for the optimal two-look procedure, does not lie above L (0) 3;1 ( ), that of the optimal one-look procedure. In the case of Figure 3(a) , the implication is that L for the twolook case is no greater than L for the one-look case, and conversely for the U 's. That is, we do not obtain a narrower initial sampling region in the two-look case, as intuition suggests. Equivalently, there is not a wider continuation region with one look remaining than with two remaining.
By obvious modi cation, DeGroot's result still holds even if the l (k) i change with k. Therefore, the conclusion of the preceding paragraph still follows. If loss depends upon the number of looks it seems natural that l 2 . Intuitively, a narrower continuation region results when the loss function speci es a greater penalty as the number of looks increases.
